Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
ACRV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $11.90
Previous CloseN/A
Volume1.72K
Average Volume (3M)176.07K
Market Cap
$47.34M
Enterprise Value$54.38M
Total Cash (Recent Filing)$99.60M
Total Debt (Recent Filing)$5.63M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 13, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding31,351,480
10 Day Avg. Volume455,092
30 Day Avg. Volume176,072
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1245.45
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$12.33Price Target Upside716.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Acrivon Therapeutics, Inc. News
PremiumCompany Announcements
Acrivon Therapeutics Appoints New Chief Medical Officer
PremiumCompany Announcements
Acrivon Therapeutics Reports 2024 Financial Results and Progress---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsData in endometrial cancer shows strong clinical benefits, with a 35% overall response rate and 80% disease control rate.
Drug DevelopmentAcrivon's OncoSignature assay improves patient selection effectiveness, potentially increasing response rates significantly compared to previous studies.
Financial StabilityThe deprioritization of certain programs is expected to have a favorable impact on the company's cash runway, extending it into 2027.
Bears Say
Financial OutlookThe need for approximately $300M additional financing through 2038 poses a financial risk.
Program DeprioritizationAcrivon is deprioritizing its ovarian and bladder cancer programs due to challenges in patient recruitment and higher efficacy expectations.
Stock PerformanceACRV shares traded down significantly following the clinical update, primarily due to the cessation of the ovarian and bladder programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.40 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $47.34M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 36 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.664 by $0.064.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,351,480 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.664. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
---
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (716.56% Upside)
$12.33 (716.56% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.42%
12-Months-Change
Fundamentals
Return on Equity
-54.07%
Trailing 12-Months
Asset Growth
42.18%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. The company leverages its proprietary precision medicine platform to identify patients most likely to benefit from its drug candidates. Acrivon's core products include advanced drug candidates designed to address specific unmet needs in cancer treatment.
---
ACRV Stock 12 Month Forecast
Average Price Target
$12.33
▲(716.56% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Blueprint Medicines
―
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-33.84%
reiterated a buy rating 7 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -33.84% per trade.
---